TCR2 Therapeutics

TCR , Inc. is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR was founded by MPM Capital and has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.
Company Growth (employees)
Cambridge, US
Size (employees)
18 (est)+13%
TCR2 Therapeutics was founded in 2015 and is headquartered in Cambridge, US

TCR2 Therapeutics Office Locations

TCR2 Therapeutics has office in Cambridge
Cambridge, US

TCR2 Therapeutics Metrics

TCR2 Therapeutics Summary

Founding Date


Total Funding

$48.3 m

Latest funding size

$44.5 m

Time since last funding

4 months


We estimate that TCR2 Therapeutics's latest funding round in December 2016 was $44.5 m. In total, TCR2 Therapeutics has raised $48.3 m

TCR2 Therapeutics Company Life

You may also be interested in